AstraZeneca: Neuromyelitis Optica trials
The registry lists 11 Neuromyelitis Optica studies with AstraZeneca as lead sponsor. 3 are open to participants now and 5 have results posted.
Phase 2 3Phase 3 8No phase 3(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Study of Ravulizumab in Chinese Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD)RecruitingNCT07557420Phase 3
- Study of Ultomiris® (Ravulizumab) Safety in PregnancyRecruitingNCT06312644
- Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor TherapiesRecruitingNCT05966467
- An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSDCompletedNCT04201262Phase 3Results posted
- A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum DisorderTerminatedNCT04155424Phase 2/3Results posted
- N-MOmentum: A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum DisordersCompletedNCT02200770Phase 2/3Results posted
- An Open Label Extension Trial of Eculizumab in Relapsing NMO PatientsCompletedNCT02003144Phase 3Results posted
- A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO (PREVENT Study)TerminatedNCT01892345Phase 3Results posted
- Epidemiological Study of Treatment Approaches on AQP4-IgG Positive NMOSD in RussiaTerminatedNCT07247292
- Efficacy, Safety, PK, PD, and ADA of Eculizumab in Chinese Adults With NMOSDActive, not recruitingNCT06724809Phase 3
- Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSDActive, not recruitingNCT05346354Phase 2/3